The EU Commission has prohibited the planned acquisition of the US biotech company Grail by Illumina. The transaction could hinder competition for a blood-based screening test for cancer, said Margrethe Vestager, the vice president in charge. She ordered Illumina to unwind the already completed $7.1 billion acquisition. The US company announced it would appeal in court.
Continue reading now
Get 30 days of free access to the Decision Brief to read these and more quality news every day.
Are you already a guest at the Europe.Table? Log in now